President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...

W hen Donald Trump’s tariffs are mentioned, you might recall his “Liberation Day” duties on uninhabited islands, his on-again ...

Finally, don't discount legal challenges to the president's tariffs. An argument could be made that pharmaceutical products ...

President Trump is reportedly pushing for higher blanket tariffs on imports from the European Union, throwing a wrench in ...

The opening salvo of second-quarter earnings calls this week came against President Donald Trump’s renewed calls for a tariff ...

Johnson and Johnson beat Wall Street’s quarterly sales expectations and raised its full-year outlook, a show of confidence as ...

Despite former President Donald Trump’s threat of a 200% tariff on imported drugs during a cabinet meeting, pharmaceutical investors have shown surprisingly positive sentiment this week. Despite ...

A 200% tariff rate — even with a delay — will have a detrimental effect on drug prices and profit margins, analysts warn.

Australia’s pharmaceutical benefits scheme is not up for negotiation, says the federal government in the face of ramped-up US ...

Already late with carrying out his administration's prior threats around pharmaceutical tariffs, President Donald Trump has ...

Drugmaker Swedish Orphan Biovitrum AB’s Chief Executive Officer Guido Oelkers said he doesn’t think tariff threats on the ...

Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong second-quarter sales of key ...